Leigh Steinberg was appointed Director of FibroBiologics, Inc., effective August 20, 2026. As of November 6, 2026, FibroBiologics, Inc. has reported 2 leadership change filings to the SEC under Item 5.02 of Form 8-K, from July 9, 2026 to August 24, 2026, naming 2 appointments (Form 8-K, August 24, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like FibroBiologics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
FibroBiologics, Inc. reported changes in 2 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-07-09 to 2026-08-24. They name 2 people. Every row below is cited to the filing it comes from, and this page adds each new change as FibroBiologics, Inc. files it.
Also on the record for FibroBiologics, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| October 13, 2026 | Form D, private offering | $1.20M sold | Form D page | Source |
| September 17, 2026 | Stake report, Schedule 13D, by Hamid Khoja | 7.5% of the class | 5%+ stakes | Source |
| September 16, 2026 | Form D, private offering | $500K sold | Form D page | Source |
| August 14, 2026 | Stake report, Schedule 13G, by Armistice Capital, LLC | 9.99% of the class | 5%+ stakes | Source |
| June 29, 2026 | Form D, private offering | $3M sold | Form D page | Source |
| April 9, 2026 | Stake report, Schedule 13G, by Lind Global Fund III LP | 4.99% of the class | 5%+ stakes | Source |
| December 16, 2025 | Form D, private offering | $1.73M sold | Form D page | Source |
| December 3, 2025 | Form D, private offering | $4M sold | Form D page | Source |
| December 3, 2025 | Form D, private offering | $1.50M sold | Form D page | Source |
| July 17, 2025 | Stake report, Schedule 13G/A, by BlackRock, Inc. | 2% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs FibroBiologics, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on FibroBiologics, Inc. and the records around it.
FibroBiologics, Inc. elsewhere on the record
- Company profile and every filing Oct 2026
- Form D filing Oct 2026
- 5%+ stake filings Sep 2026
- Form D filing Sep 2026
- Who owns it
Companies that share a holder
- Lind Global Fund III LP also filed stake reports on 11 other companies: Dare Bioscience, Inc. (Aug 2026), DEFSEC Technologies Inc. (Aug 2026), Enveric Biosciences, Inc. (Aug 2026)
- Armistice Capital, LLC also filed stake reports on 120 other companies: Autolus Therapeutics plc (Aug 2026), Bicycle Therapeutics plc (Aug 2026), BioXcel Therapeutics, Inc. (Aug 2026)
- BlackRock, Inc. also filed stake reports on 1596 other companies: AvePoint, Inc. (Nov 2026), BIOMARIN PHARMACEUTICAL INC (Nov 2026), MSG RANGERS CORP (Nov 2026)
Watch FibroBiologics, Inc.
Get an email when FibroBiologics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on FibroBiologics, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on FibroBiologics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on FibroBiologics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
12 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-08-24 | In | Director | 2026-08-20 | 8-K, 2026-08-24 | |
| 2026-07-09 | In | Director | 2026-07-08 | 8-K, 2026-07-09 |
Who leads FibroBiologics, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Director: Leigh Steinberg, appointed, effective 2026-08-20 (filed 2026-08-24).
New leaders reset buying decisions — get the Full Report on FibroBiologics, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportWatch FibroBiologics, Inc. (free up to 3)
Find people with the same kind of experience as the Director at FibroBiologics, Inc., with the record behind each one.
Find candidates like Director at FibroBiologics, Inc.Every change, in the filing's words
Appointed: Leigh Steinberg, Director, effective 2026-08-20
On August 20, 2026, the Board of Directors (the "Board") of FibroBiologics, Inc. (the "Company") appointed Leigh Steinberg as a Class II director of the Board, effective August 20, 2026, to serve until the expiration of his term at the 2028 annual meeting of stockholders.
- In connection with his appointment, Mr. Steinberg will be entitled to receive compensation consistent with that of the Company's other non-employee directors under the Company's Non-Employee Director Compensation Policy, as such policy may be amended from time to time.
- The Company also entered into its standard form of indemnification agreement with Mr. Steinberg, which will require the Company to indemnify Mr. Steinberg against certain liabilities that may arise as a result of his status or service as a director of the Company.
Appointed: Kathleen Rubins, Director, effective 2026-07-08
On July 8, 2026, the Board appointed Kathleen Rubins, Ph.D. as a Class III director of the Board, effective July 8, 2026, to serve until the expiration of her term at the 2029 annual meeting of stockholders.
- On July 2, 2026, Matt Link notified FibroBiologics, Inc. (the "Company") that he was resigning from the Board of Directors (the "Board"), effective as of July 2, 2026.
- Dr. Rubins was also appointed to serve on the Board's Audit Committee, Compensation Committee and Governance and Nominating Committee.
- Dr. Rubins is the Founding Director, Trivedi Institute for Space and Global Biomedicine, and a Professor of Computational and Systems Biology at the University of Pittsburgh School of Medicine.
- She is also a US Army Reserve Innovation Officer, Major/O-4 in the 75 th US Army Innovation Command.
- From August 2009 through July 2025, Dr. Rubins served as an Astronaut in the National Aeronautics and Space Administration (NASA).
- Dr. Rubins received her Ph.D. in Cancer Biology from Stanford University and a Bachelor of Science in Molecular Biology from the University of California, San Diego (UCSD).
- In connection with her appointment, Dr. Rubins will be entitled to receive compensation consistent with that of the Company's other non-employee directors under the Company's Non-Employee Director Compensation Policy, as such policy may be amended from time to time.
FibroBiologics, Inc.'s funding history
Tools for this story
Each opens in a new tab, filled in for FibroBiologics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.